The Vanguard Group 13D and 13G filings for Regeneron Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:12 pm Purchase |
2023-12-29 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
The Vanguard Group | 8,838,240 8.250% |
115,792 (+1.33%) |
Filing |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
The Vanguard Group | 8,722,448 8.150% |
563,933 (+6.91%) |
Filing |
| 2022-02-10 08:32 am Purchase |
2021-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
The Vanguard Group | 8,158,515 7.720% |
227,295 (+2.87%) |
Filing |
| 2021-02-10 11:47 am Purchase |
2020-12-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
The Vanguard Group | 7,931,220 7.560% |
1,678,917 (+26.85%) |
Filing |